Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
Chinese Patent Office

Generated: December 16, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,364,842

« Back to Dashboard

Claims for Patent: 5,364,842

Title: Method of producing analgesia
Abstract:A method of producing analgesia and enhancing opiate analgesia is disclosed. The method includes administering TVIA (SNX-185) or MVIIA (SNX-111) omega-conopeptide, or derivative thereof which is characterized by its ability to (a) inhibit voltage-gated calcium channels selectively in neuronal tissue, as evidenced by the peptide's ability to inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind to omega-conopeptide MVIIA binding sites present in neuronal tissue.
Inventor(s): Justice; Alan (Sunnyvale, CA), Singh; Tejinder (Palo Alto, CA), Gohil; Kishor C. (Richmond, CA), Valentino; Karen L. (San Carlos, CA)
Assignee: Neurex Corporation (Menlo Park, CA)
Application Number:08/081,863
Patent Claims: 1. A method of producing analgesia in a mammalian subject, comprising

administering to the subject, in the absence of an opiate, an omega conopeptide selected from the group consisting of TVIA (SNX-185), MVIIA (SNX-111) and derivatives thereof, wherein said omega conopeptide is effective (a) to inhibit electrically stimulated contraction of the guinea pig ileum, and (b) to bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue.

2. The method of claim 1, wherein the activities of the omega-conopeptide in calcium channel inhibition and in binding to the MVIIA binding site are within the ranges of such activities of omega-conopeptides MVIIA and TVIA.

3. The method of claim 1, wherein the omega-conopeptide is MVIIA or TVIA.

4. The method of claim 1, wherein the omega-conopeptide is administered intrathecally.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
US Army
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: